



1636  
FT5/3  
3-14-01

Patent Docket P 61R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Avi J. Ashkenazi et al.  Serial No.: 09/603,866  Filed: June 26, 2000  For: METHODS FOR MAKING APO-2 LIGAND USING DIVALENT METAL IONS	Group Art Unit: 1636  Examiner: To Be Assigned
<p style="text-align: center;"><b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p style="text-align: center;">February 16, 2001</p> <p style="text-align: center;"><i>Diane L. Marschang</i> Diane L. Marschang</p>	

**COMMUNICATION RE CITED ART REFERENCE**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

On December 8, 2000, Applicants filed an Information Disclosure Statement and Form 1449. On the Form 1449, it was indicated (by an asterisk \*) that reference number 64, Otwinowski et al., was not included with the copies of the remainder of the cited references. Applicants have now obtained a copy of the Otwinowski et al. reference, and a copy of that reference is included with this Communication. A copy of the previously filed Form 1449 is also enclosed for the Examiner's convenience. Consideration of all the references cited on the Form 1449 is respectfully requested.

Respectfully submitted,

GENENTECH, INC.

By: *Diane L. Marschang*  
Diane L. Marschang  
Reg. No. 35,600

Date: February 16, 2001

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-5416  
Fax: (650) 952-9881

CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- 37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- 37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those items which are marked with an asterisk (\*) are not supplied.

Item number 64 is not supplied with this Information Disclosure Statement.

A copy of the PCT Search Report is supplied herewith.

A concise explanation of relevance of the items listed on PTO-1449 is:

- not given
- given for each listed item
- given for only non-English language listed item(s) [Required]
  - For Item number 1 (EP 417,563), an English abstract is attached.
  - For Item number 6 (WO 97/23615), an English abstract is attached.
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to

be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: December 8 2000

By: Diane L. Marschang  
Diane L. Marschang  
Reg. No. 35,600  
Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE



Patent Docket P1761R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>Re Application of Avi J. Ashkenazi et al. Serial No.: 09/603,866 Filed: June 26, 2000 For: METHODS FOR MAKING APO-2 LIGAND USING DIVALENT METAL IONS</p>	<p>Group Art Unit: 1636 Examiner: To Be Assigned</p> <p><b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>December 8, 2000</p> <p><i>Eileen Ly</i></p>
---	--

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

**37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

**37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

**37 CFR §1.97(d)**

- after the period specified in 37 CFR §1.97(c), and is accompanied by the fee set forth in 37

TECH CENTER 1600/2900  
FEB 26 2001  
RECEIVED